Another immuno-oncology company kicking butt: T

Another immuno-oncology company kicking butt:

Trillium Therapeutics Shares Soar Over 40% on $25 Million Pfizer Investment, Impressive TTI-622’s Safety Profile
FX Empire
Vivek Kumar
,FX Empire•September 9, 2020

Trillium Therapeutics Shares Soar Over 40% on $25 Million Pfizer Investment, Impressive TTI-622’s Safety Profile
More
Trillium Therapeutics, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, said it received an equity investment of $25 million from the pharma giant Pfizer Inc; also investors remain upbeat over the impressive safety profile of TTI-622, an antibody-like fusion protein to be used for treating cancer, sending the stock soaring in after-hours trading on Tuesday.

Trillium Therapeutics’ shares jumped over 40% to $13.37 in after-hours trading. Also, the stock is up over 800% so far this year after closing at $1.03 in 2019.

Trillium Therapeutics said that it has agreed to sell nearly 2.3 million of its common shares at a price of $10.88 per share to Pfizer for gross proceeds of $25.0 million. The offering is expected to close on or about September 10, 2020.